UFP-101 TFA

Cat. No.: HY-P1299A

Molecular Formula: $C_{84}H_{139}F_3N_{32}O_{23}$

Molecular Weight: 2022.19

Sequence Shortening: Bn-GGGFTGARKSARKRKNQ-NH2

Target: Opioid Receptor

Pathway: GPCR/G Protein; Neuronal Signaling

Storage: Sealed storage, away from moisture and light

Powder -80°C 2 years

-20°C 1 year

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)

Bn-GGGFTGARKSARKRKNQ-NH_2 (TFA salt)

SOLVENT & SOLUBILITY

In Vitro

H_2O : 130 mg/mL (64.29 mM; Need ultrasonic)

Preparing Stock Solutions	Solvent / Mass / Concentration	1 mg	5 mg	10 mg
	1 mM	0.4945 mL	2.4726 mL	4.9451 mL
	5 mM	0.0989 mL	0.4945 mL	0.9890 mL
	10 mM	0.0495 mL	0.2473 mL	0.4945 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

1. Add each solvent one by one: PBS
   Solubility: 100 mg/mL (49.45 mM); Clear solution; Need ultrasonic

BIOLOGICAL ACTIVITY

Description

UFP-101 TFA is a potent, selective, and competitive antagonist of the N/OFQ peptide (NOP) receptor, with a pK_i of 10.24. UFP-101 TFA displays >3000-fold selectivity over δ, μ and κ opioid receptors. UFP-101 TFA shows antidepressant-like effect[1][2].

In Vivo

UFP-101 TFA elicits a pronounced acute and dosedependent antidepressant-like effect in mice submitted to the forced swimming test (FST)[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Calo G, et al. [Nphe^{1},Arg^{14},Lys^{15}]nociceptin-NH_2, a novel potent and selective antagonist of the nociceptin/orphanin FQ receptor. Br J Pharmacol. 2002;136(2):303-311.

[2]. Gavioli EC, et al. Blockade of nociceptin/orphanin FQ-NOP receptor signalling produces antidepressant-like effects: pharmacological and genetic evidences from the mouse forced swimming test. Eur J Neurosci. 2003;17(9):1987-1990.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA